A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

NCT04039607 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma

NCT02576509 ·Status: COMPLETED ·Phase: PHASE3

GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma

NCT05178043 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)

NCT04658147 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

NCT05199285 ·Status: TERMINATED ·Phase: PHASE2

A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer

NCT02828124 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients

NCT05281926 ·Status: UNKNOWN ·Phase: PHASE1

Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma

NCT03382886 ·Status: TERMINATED ·Phase: PHASE1

Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)

NCT00071994 ·Status: COMPLETED ·Phase: PHASE2

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

NCT03510871 ·Status: COMPLETED ·Phase: PHASE2

Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer

NCT03439891 ·Status: COMPLETED ·Phase: PHASE2

Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma

NCT03841201 ·Status: COMPLETED ·Phase: PHASE2

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

NCT03695250 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

NCT05822752 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

NCT04567615 ·Status: COMPLETED ·Phase: PHASE2

Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer

NCT03222076 ·Status: COMPLETED ·Phase: PHASE2

A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer

NCT04340193 ·Status: COMPLETED ·Phase: PHASE3

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

NCT06413017 ·Status: RECRUITING ·Phase: PHASE2

A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)

NCT06487559 ·Status: RECRUITING ·Phase: PHASE1

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

NCT05223816 ·Status: RECRUITING ·Phase: PHASE2

Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer

NCT03211416 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer

NCT00355238 ·Status: COMPLETED ·Phase: PHASE2

Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)

NCT01540461 ·Status: COMPLETED ·Phase: PHASE1

SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer

NCT00095992 ·Status: COMPLETED ·Phase: PHASE2

Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC

NCT04611165 ·Status: COMPLETED ·Phase: PHASE2